CompanyCOAGNasdaqCambridge, MA

Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics develops therapies for blood coagulation disorders.

SEC EDGAR ClinicalTrials.gov hemab.com

8-KSep 24Latest SEC filing, period to Sep 24

Sep 24Latest story

September 2026

Hemab Therapeutics adds Keli Walbert to board and audit committee

Sep 24PeopleHemab Therapeutics Holdings, Inc.

August 2026

Hemab reports Q2 2026 results as FDA clears sutacimig path to Phase 3 in Glanzmann thrombasthenia

Aug 11Quarterly updateHemab Therapeutics Holdings, Inc.